SION Sionna Therapeutics, Inc.
$7.85▲ +3.02%
Healthcare
Other
After hours
$7.85▲ +0.00%
Sep 11, 7:59 PM ET
Volume 1.21M
Avg Volume (10D) 1.10M
Key Metrics & Fundamentals
Market Cap
$354.43M
P/E Ratio
–
Div Yield
–%
52W Range
4.01 - 54.97
% vs 50 MA
-70.91%
% vs 200 MA
-78.49%
RSI-14
31.7
MACD Histogram
+1.5600
Beta (1Y vs SPY)
1.07
Free Cash Flow
-$22.22M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$31.84M
COGS
–
Operating Exp
$32.47M
Operating Income
-$32.47M
EBIT
-$32.47M
Pretax Income
-$29.89M
Net Income
-$29.89M
EPS (Diluted)
-0.66
Price & Volume History
Loading chart…
Recent News
Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead
Motley Fool · Aug 20, 2026 7:50 PM
Sionna Therapeutics (SION) Resets After Trial Miss, Is The Discount Now Too Deep?
Simply Wall St. · Aug 13, 2026 9:11 AM
Sionna Therapeutics (SION) Is Down 86.8% After Halting SION-719 And Refocusing Its CF Pipeline – Has The Bull Case Changed?
Simply Wall St. · Aug 13, 2026 5:13 AM
Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says
MT Newswires · Aug 12, 2026 3:02 PM
Sionna Therapeutics (SION) Stock Still Looks Cheap After The 90% Fall
Simply Wall St. · Aug 12, 2026 10:12 AM
One Company’s Clinical Miss Is Another’s Moat: Vertex Rallies as Sionna’s CF Bet Collapses
Insider Monkey · Aug 12, 2026 3:41 AM
Sionna Therapeutics stock falls 92% after SION-719 trial failure
Quartz · Aug 11, 2026 1:11 PM
BTIG Downgrades Sionna Therapeutics to Neutral From Buy
MT Newswires · Aug 11, 2026 11:36 AM
Sionna Therapeutics (SION) Halts Lead Cystic Fibrosis Drug After Phase 2 Failure
Simply Wall St. · Aug 11, 2026 8:12 AM
Sionna Halts SION-719 After Phase 2a Miss, Eyes SION-451 Combination Path
MarketBeat · Aug 11, 2026 4:03 AM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See SION's money flow as a full page
Social Sentiment
No Reddit posts found for SION.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.